Details:
Norethisterone acts similarly to endogenous progesterone with a much higher potency, it acts at the pelvic level to alter cervical and endometrial function, as well as via the inhibition of pituitary hormones that play a role in follicular maturation and ovulation.
Lead Product(s): Norethisterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Emzahh-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
The generic version of Taytulla®1 Capsules, Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg, has received approval by the United States Food & Drug Administration.
Lead Product(s): Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Norethindrone Acetate/Ethinyl Estradiol/Ferrous Fumarate-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2022
Details:
Tidilan is currently available in tablet and injectable dosage forms. BSV has some of the leading women’s health brands such as Rhoclone, Hucog, Hucog 5000 HP, AntiD among others.
Lead Product(s): Isoxsuprine Hydrochloride
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Tidilan
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Bharat Serums & Vaccines ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 05, 2022
Details:
The portfolio acquired comprises eight U.S. FDA approved ANDAs and two products pending approval. It includes generic products in female hormones which will be manufactured at Naari’s dedicated female hormone facility in India and commercialized over the next 24 months.
Lead Product(s): Undisclosed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Approved Product Type: Undisclosed
Partner/Sponsor/Collaborator: Naari
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 10, 2020